<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820794</url>
  </required_header>
  <id_info>
    <org_study_id>A5361034</org_study_id>
    <nct_id>NCT00820794</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of
      lithium by co-administering both drugs to healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional Study Purpose Details: To investigate potential drug-drug interaction between PD
      0332334 and lithium
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lithium pharmacokinetic endpoints: area under curve from 0 to infinity (AUCinf), area under curve from 0 to last quantifiable concentration (AUClast), half-life (T1/2), and maximum serum concentration (Cmax).</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; clinical safety lab; 12-lead ECG; and vital signs will be monitored in this study.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No Secondary Outcomes</measure>
    <time_frame>No Secondary Outcomes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Generalized Anxiety Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment</description>
    <arm_group_label>Cohort 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>225 mg q12h PD 0332334, oral, 9 days treatment</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <other_name>imagabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout</description>
    <arm_group_label>Cohort 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD 0332334</intervention_name>
    <description>225 mg q12h PD 0332334, oral, 9 days treatment</description>
    <arm_group_label>Cohort 1b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and/or females

          -  Age from 21 to 55 (inclusive)

          -  BMI ranges from 18 to 30 kg/m2

        Exclusion Criteria:

          -  Previous participation in a PD 332334 study

          -  Pregnant or nursing females

          -  Hypersensitivity (allergic) to lithium, Neurontin (gabapentin), or Lyrica (pregabalin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5361034&amp;StudyName=A%20Phase%201%20Study%20To%20Estimate%20The%20Effects%20Of%20PD%200332334%20On%20Lithium%20Pharmacokinetics%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Drug-drug interaction, lithium, PD 0332334, pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

